Table 4 Diagnostic performance of LI-RADS v2018 and non-invasive model in each cohort
From: Non-invasive diagnosis strategy of hepatocellular carcinoma in low-risk population
Model | AUC % (95% CI) | ACC (no.) | SEN (no.) | SPE (no.) | PPV (no.) | NPV (no.) | |
|---|---|---|---|---|---|---|---|
Training cohort n = 324 | LI-RAD v2018 | 81.6 (77.0–86.1) | 83.0 (269/324) | 76.8 (86/112) | 86.3 (183/212) | 74.8 (86/115) | 87.6 (183/209) |
Imaging model | 90.0 (86.3–93.6) | 75.3 (244/324) | 31.3 (35/112) | 98.6 (209/212) | 92.1 (35/38) | 73.1 (209/286) | |
Clinical model | 95.4 (93.0–97.8) | 89.2 (289/324) | 77.7 (87/112) | 95.3 (202/212) | 89.7 (87/97) | 89.0 (202/227) | |
Internal validation cohort n = 139 | LI-RAD v2018 | 81.2 (74.6–87.8) | 81.3 (113/139) | 80.7 (50/62) | 81.8 (63/77) | 78.1 (50/64) | 84 (63/75) |
Imaging model | 85.9 (79.3–92.4) | 74.1 (103/139) | 51.6 (32/62) | 92.2 (71/77) | 84.2 (32/38) | 70.3 (71/101) | |
Clinical model | 93.1 (88.6–97.5) | 88.5 (123/139) | 79.0 (49/62) | 96.1 (74/77) | 94.2 (49/52) | 85.1 (74/87) | |
External validation cohort n = 218 | LI-RAD v2018 | 73.6 (67.8–79.4) | 73.4 (160/218) | 78.9 (82/104) | 68.4 (78/114) | 69.5 (82/118) | 78.0 (78/100) |
Imaging model | 81.3 (75.5–87.1) | 71.6 (156/218) | 53.9 (56/104) | 87.7 (100/114) | 80.0 (56/70) | 67.6 (100/148) | |
Clinical model | 90.2 (86.0–94.4) | 85.3 (186/218) | 81.7 (85/104) | 88.6 (101/114) | 86.7 (85/98) | 84.2 (101/120) |